Axsome Therapeutics (AXSM) Invested Capital (2015 - 2026)

Axsome Therapeutics has disclosed Invested Capital across 12 years of filings, most recently posting $65.7 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $65.7 million, down 71.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.7 million (down 71.81% YoY), and the FY2025 annual result was $208.3 million, down 12.12% from the prior year.
• Invested Capital came in at $65.7 million for Q1 2026 at Axsome Therapeutics, down from $208.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $458.8 million in Q2 2023 to a low of $64.7 million in Q1 2022.
• The 5-year median for Invested Capital is $233.2 million (2025), against an average of $240.2 million.
• Across the five-year window, Invested Capital soared 316.34% in 2023 and tumbled 71.81% in 2026, its largest moves.
• Axsome Therapeutics' Invested Capital stood at $204.6 million in 2022, then jumped by 81.36% to $371.0 million in 2023, then sank by 36.11% to $237.0 million in 2024, then retreated by 12.12% to $208.3 million in 2025, then slumped by 68.44% to $65.7 million in 2026.
• The last three Invested Capital figures came in at $65.7 million (Q1 2026), $208.3 million (Q4 2025), and $193.7 million (Q3 2025), per Business Quant data.